For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Attruby represents a significant advancement . These innovative therapies preserve the transthyretin protein, slowing its damaging build-up and alleviating the severity of the illness. Individuals are now experiencing